Fling Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 9.98 M
as on 23-10-2024
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.10 Cr
as on 23-10-2024
- Revenue 29.19%
(FY 2023)
- Profit 71.65%
(FY 2023)
- Ebitda 65.64%
(FY 2023)
- Net Worth 46.23%
(FY 2023)
- Total Assets 11.91%
(FY 2023)
About Fling Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.98 M.
The company currently has active open charges totaling ₹5.10 Cr.
Madhu Nair, Biju Namboodiri, and David Palayoor serve as directors at the Company.
- CIN/LLPIN
U24232KL2005PTC018835
- Company No.
018835
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Nov 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thrissur, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Fling Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhu Nair  | Managing Director | 05-May-2023 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Biju Namboodiri | Whole-Time Director | 11-Mar-2009 | Current |
| David Palayoor | Whole-Time Director | 18-Nov-2005 | Current |
Financial Performance of Fling Pharmaceuticals.
Fling Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 29.19% increase. The company also saw a substantial improvement in profitability, with a 71.65% increase in profit. The company's net worth Soared by an impressive increase of 46.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fling Pharmaceuticals?
In 2023, Fling Pharmaceuticals had a promoter holding of 23.34% and a public holding of 76.66%. The company had 2 Subsidiaries and 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sreeparna Pharmaceutical Distributors Private LimitedActive 15 years 5 monthsMadhu Nair is a mutual person
- Ave Health Care Private LimitedActive 21 years 1 month
Biju Namboodiri and David Palayoor are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dhanlaxmi Bank Limited Creation Date: 03 Aug 2020 | ₹2.73 M | Open |
Dhanlaxmi Bank Limited Creation Date: 06 Oct 2018 | ₹3.25 M | Open |
Dhanlaxmi Bank Limited Creation Date: 17 Apr 2018 | ₹1.62 Cr | Open |
How Many Employees Work at Fling Pharmaceuticals?
Fling Pharmaceuticals has a workforce of 40 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fling Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fling Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
